Truth be told, one of the biggest draws to using CBD oil for pain has been the fact that it has little distinguishable side-effects or contraindications with other medications. In fact, in a massive report that was published by the World Health Organization during last year’s 2017 Expert Committee on Drug Dependence, it was (finally) declared to the world that CBD is a “safe, well tolerated [compound, which] is not associated with any significant adverse public health effects.”
Many people who decide to use CBD oil use it for treating contact dermatitis. This kind of problem might be due to a reaction when coming into contact with an allergen, or coming into contact with a chemical, like a detergent, that irritates your skin. It isn't a really serious condition, however at times the reaction can be unpleasant and severe.
Since there are so many differences between industrial hemp and high-THC marijuana, it seems to make sense that it would be a fostered, rather than demonized crop. Although technically hemp is not illegal to grow, it requires obtaining a special permit from the DEA. These permits are rarely given out and require that the crop be surrounded by security measures such as fences, razor wire, security guards, or dogs. For a crop that has little-to-no potential to get people high, the current attitude is both irresponsible and draconian.
In the UK, the Department for Environment, Food and Rural Affairs treats hemp as a purely non-food crop, but with proper licensing and proof of less than 0.2% THC concentration, hemp seeds can be imported for sowing or for sale as a food or food ingredient. In the U.S., imported hemp can be used legally in food products and, as of 2000, was typically sold in health food stores or through mail order.
These are just a few specific instances that show how effective CBD oil can be, laying the groundwork for CBD oil being recognized as a justifiable medicine for a variety of ailments. As a result, many states are passing legislation rapidly allowing CBD oil to be used in numerous clinical studies as treatment plans. Research continues to back up it legitimacy and programs are being funded globally to continue the studies.
Regarding your comment on CBD and colitis or inflammatory bowel disease. Immune cells patrol the gut to ensure that harmful microbes hidden in the food we eat do not sneak into the body. Cells that are capable of triggering inflammation are balanced by cells that promote tolerance, protecting the body without damaging sensitive tissues. When the balance tilts too far toward inflammation, inflammatory bowel disease can result. Now, researchers have found that a kind of tolerance-promoting immune cell appears that carry a specific bacterium in guts called Lactobacillus reuteri that is the normal part of the gut microbiome, and tryptophan, part of a protein-rich diet, soothes the inflamed gut because it increases the development of a population of immune cells that promote tolerance. Further, the bacterium needs tryptophan — one of the building blocks of proteins — to trigger the cells’ appearance, and the more tryptophan in the diet to feed the gut bacterium, Lactobacillus reuteri, the more of these immune cells there are.
Under federal law, cannabis (from which both CBD and marijuana are derived) is illegal everywhere, although the laws against it aren’t generally enforced in states that have legalized marijuana. Some manufacturers claim that CBD culled from legally imported industrial hemp, which has little to no THC, is fine to ship across the U.S., but many experts disagree, noting that because hemp comes from the same species as marijuana, cannabis sativa, all CBD falls under the DEA’s Schedule 1 designation. “This creative interpretation of the law runs afoul of reality,” says the Brookings Institution, a Washington, DC, think tank.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160